論文・技術情報追加のお知らせ

1. Disproportionality Analysis of Tirzepatide-Associated Ketoacidosis.

チルゼパチド関連のケトアシドーシスリスクをFAERSで解析。

対象DB：FAERS

2. Post-marketing safety profile of palivizumab: a 20-year pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS).

パリビズマブの20年間の市販後安全性をFAERSで系統解析。

対象DB：FAERS

3. Immune checkpoint inhibitors and myocarditis-myositis-myasthenia gravis overlap: a FAERS pharmacovigilance study with time-to-onset characterization.

ICIによる心筋炎・筋炎・重症筋無力症重複リスクと発現時期。

対象DB：FAERS

4. Risk factors for drug-related impaired gastric emptying: a pharmacovigilance analysis of the FDA adverse event reporting system.

薬剤性胃排出能低下のリスク因子をFAERSデータに基づき解析。

対象DB：FAERS

5. Comparative Adverse Event Reporting of Asparaginase-Containing Induction Regimens in Pediatric Acute Lymphoblastic Leukemia Using the United States Food and Drug Administration Adverse Event Reporting System.

小児ALLへのアスパラギナーゼ導入レジメンの副作用を比較。

対象DB：FAERS

6. A Real-world Pharmacovigilance Study of the FAERS Database: Safety Signals of Common Medications for Non-infectious Uveitis.

非感染性ぶどう膜炎の一般治療薬の安全シグナルをFAERSで解析。

対象DB：FAERS

7. Assessing the Risk of Drug-Induced Influenza-Like Illness: A Disproportionality Analysis of Two Decades of FAERS Data (2004-2025).

薬剤性インフルエンザ様疾患のリスクを20年間のFAERSで解析。

対象DB：FAERS

8. Pharmacovigilance Assessment of Thrombotic Adverse Events Linked to GLP-1 Receptor Agonists: Analysis of FAERS Reports from 2020-2025.

GLP-1受容体作動薬に関連する血栓性副作用の薬物監視評価。

対象DB：FAERS

9. From real-world pharmacovigilance data to clinical practice: a geriatric-specific predictive model for immune-related adverse events in lung cancer based on routine clinical indicators.

肺がん患者での免疫関連副作用を予測する高齢者特異的モデル。

対象DB：FAERS

10. Uncovering drug-associated risk signals for neovascular age-related macular degeneration: an integrative pharmacovigilance and proteogenomic study.

新生血管性加齢黄斑変性の薬剤関連リスク信号と生物学的機序。

対象DB：FAERS

11. Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

高用量抗VEGF薬による眼内炎症リスクをリアルワールド解析。

対象DB：FAERS

12. Severe Cutaneous Adverse Reactions Associated With Newer-Generation Antiseizure Medications: A Real-World Pharmacovigilance Study Based on FAERS and JADER.

新世代抗てんかん薬による重症皮膚副作用のリアルワールド解析。

対象DB：JADER

13. Efficacy and safety of repetitive transcranial magnetic stimulation in anorexia and bulimia nervosa: a systematic review and meta-analysis.

拒食症・過食症への反復経頭蓋磁気刺激の有効性と安全性の評価。

対象DB：JADER

14. Characterizing Clinical Patterns and Associated Factors of Zinc-Induced Copper Deficiency: Insights from Large-Scale Pharmacovigilance Databases.

亜鉛療法による銅欠乏症の臨床パターンと関連因子を包括解析。

対象DB：JADER,VigiBase

15. Post-marketing safety profile of bictegravir/emtricitabine/tenofovir alafenamide: a FAERS pharmacovigilance study with EudraVigilance validation and mechanistic investigation of pancreatitis.

ビクテグラビル等の市販後安全性と膵炎リスクのメカニズム解析。

対象DB：EudraVigilance

16. A comparison of antibiotic resistance reports in pharmacovigilance databases and conventional surveillance across "One Health".

副作用DBと従来の監視による抗菌薬耐性報告の比較。

対象DB：EudraVigilance,VigiBase

17. Ocular toxicity associated with Ethambutol in the South-East Asia Region.

東南アジア地域におけるエタンブトール関連の眼毒性の評価。

対象DB：VigiBase

18. Patterns of pregabalin misuse: Need for intervention.

プレガバリンの誤用・乱用パターンの特徴と対策への提言。

対象DB：VigiBase

19. Metoclopramide and Risk of Pheochromocytoma Crisis: A Causality Assessment Using Literature and VigiBase Data.

メトクロプラミドによる褐色細胞腫危機のリスクと因果関係評価。

対象DB：VigiBase

20. Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.

新生児・乳児のシロリムス療法に伴う脂質異常症のコホート解析。

対象DB：VigiBase

21. Virtual internal exposures of lansoprazole administered to cytochrome P450 2C19 poor metabolizers estimated by simplified physiologically based pharmacokinetic modeling.

CYP2C19代謝不全者でのランソプラゾール仮想内部曝露量の推計。

対象DB：JADER

22. Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan.

日本の尋常性乾癬患者におけるニメキズマブの費用対効果分析。

対象DB：DPC

23. After total hip arthroplasty, patients with glucocorticoid-treated osteonecrosis of the femoral head have a higher risk of in-hospital reoperation: a nationwide propensity score-matched analysis.

糖質コルチコイド治療の大腿骨頭壊死症での人工股関節再手術リスク。

対象DB：DPC

24. Incidence of hospitalized abusive head trauma among infants in Japan, 2014-2022.

日本における乳幼児の頭部外傷（AHT）の入院発症率の推移。

対象DB：DPC

25. Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan.

日本の非小細胞肺がんの癌悪液質に対する治療薬の費用対効果。

対象DB：JMDC

26. Trends, Demographic Characteristics, and Seasonal Patterns of Nonoperative and Operative Reduction for Intussusception: A Preliminary Nationwide Claims-Based Analysis from 2014 to 2023 in Japan.

日本の腸重積症に対する非手術的・手術的整復の動向と地域差。

対象DB：NDB

27. Definitions and Prognoses of Persistent Inflammation, Immunosuppression, and Catabolism Syndrome: A Comparative Analysis via Systematic Review and Observational Study in Japan.

持続性炎症・免疫抑制・異化症候群（PICS）の定義と予後解析。

対象DB：MDV

28. A machine-learning approach to predict additional treatment after Bacillus Calmette-Guerin induction in non-muscle-invasive bladder cancer.

機械学習を用いたBCG注入後の追加治療の予測モデルの構築。

対象DB：MDV

29. A comparative analysis of Prontosan versus saline in hard-to-heal lower limb ulcers using real-world data.

難治性下肢潰瘍へのプロントザンと生理食塩水の効果の比較。

対象DB：CPRD

30. Empirical estimate for the indirect healthcare costs of sickle cell disease from a retrospective cohort study in England between 2007 and 2019.

英国のデータを用いた鎌状赤血球症の間接医療費の推計。

対象DB：CPRD

31. Trends in Second-Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population-Based Study, 2019-2024.

2型糖尿病患者における2次治療開始動向の年齢・フレイル差。

対象DB：CPRD

32. The use of the electronic frailty index to optimise HbA1c targets in older individuals with type 2 diabetes.

高齢2型糖尿病患者のHbA1c目標最適化への電子フレイル指標の活用。

対象DB：CPRD

33. Recording of wider determinants of health in UK primary care using the Clinical Practice Research Datalink (CPRD) databases, a descriptive cross-sectional study.

英国プライマリケアにおける健康の社会的決定因子の記録状況調査。

対象DB：CPRD

34. Prescribing of anti-dementia medications in primary care: A retrospective cohort study in 1489 English General Practices.

英国の一般診療における抗認知症薬処方の実態に関するコホート研究。

対象DB：CPRD

35. Trends in Multi-dose Drug Dispensing Amongst Older Adults in Sweden: A Nationwide Repeated Cross-Sectional Register Study, 2014-2023.

スウェーデンの高齢者における複数薬品の一包化調剤の動向調査。

対象DB：CPRD

36. Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction-Associated Steatohepatitis.

代謝機能障害関連脂肪肝炎（MASH）患者の心血管疾患リスク予測。

対象DB：CPRD

37. Characteristics, all-cause healthcare resource utilisation, and costs among high-risk adults with long COVID during Omicron predominance, 2022-2023: a retrospective cohort study using UK primary care data.

オミクロン株流行期における高リスク成人ロングCOVIDの医療費推計。

対象DB：THIN

38. Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.

慢性特発性蕁麻疹へのレミブルチニブの安全性をプール解析で評価。

対象DB：CVAR

39. Incidence of Skin Infections in Patients with Atopic Dermatitis Treated with Topical Medications: A Cohort Study Using Japanese Claims Data.

日本のデータを用いた外用薬治療中のアトピー患者の皮膚感染率。

対象DB：DeSC